• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SU850000A3
    申请号:SU782674602
    申请日:1978-10-17
    公开日:1981-07-23
    发明作者:Джеймс Нельсон Альбин
    申请人:Пфайзер Инк (Фирма)；
    IPC主号:
    专利说明:

    (54.) METHOD FOR PRODUCING PYRROLIDINE DERIVATIVES
    one
    This invention relates to a process for the preparation of pyrrolidine derivatives of the general formula
    W
    y-cbX is CQOR where R is phenyl or a phenoxy group; hydrogen, methyl or ethyl; W is simple or cis Double bond; Z is simple or trans double bond; M - group or with pharmacological activity. A known method for producing tertiary amines is that the secondary amine is reacted with an organic halide. I The purpose of the invention is to prepare new pharmacologically active pyrrolidine derivatives of general formula I based on the use of this known reaction.
    The objective is achieved in that according to the method for producing pyrrolidine derivatives of the general formula I, a compound of the general formula
    ig
    CHiOT, where T is a tetrahydropyranyl or dimethyl-tert-butylsilyl group, exposed the Ü1 T to a compound of the general formula I -1 IW C O O R where WR have the above values and X is chlorine, bromine or iodine, remove the protective group T , the resulting alcohol is oxidized to an aldehyde, which is treated with a phosphonate of the general formula IV (R, jO) 2 P (0) CH, COCHaR, where R has the above values, f (is alkyl with 1–3 carbon atoms, followed by reduction of the compound Formula 1, where M is oxygen, and, if necessary, by hydrogenation
    l obtain compounds of common forums 1, where W is a simple link, with the subsequent allocation of the target product.
    The lithium salt of pyrolidone of the general formula II is subjected to alkylation by contacting a solution of a compound of the general formula M in an inert organic solvent, such as tetrahydrofuran, diethoxyethane or dioxane, with a base, such as n-butyl lithium, phenyl lithium or sodium hydride at ambient temperature to the boiling point solvent, preferably at ambient temperature. Before the alkylation, the entire base is required to react, which usually takes from 1 to 4 hours. A mixture of the alkylating agent is then added in a polar aprotic organic solvent, such as dimethylformamide or dimethylacetamide, at ambient temperature to boiling point.
    The oxidation to aldehyde is carried out in an inert hydrocarbon solvent, such as toluene, xylene or benzene mixed with dimethyl sulfoxide, in the presence of a weak acid, such as acetic acid or pyridinium trifluoroacetate. Water-soluble diimide, such as diethylcarbodiimide or dimethylaminopropylethylcarbodiimide, or, if necessary, its hydrochloride, is used as the oxidizing agent at ambient temperature. A complex of chromium trioxide and pyridine can also be used as an oxidizing agent.
    The reaction of the aldehyde with the phosphonate is carried out in an ether solvent, such as tetrahydrofuran, dimethoxyethane or dioxane, at a temperature from 0 ° C to. If necessary, lithium triethylborohydride is used as a reducing agent, as well as other selective reducing agents that cause reduction of the ketone without affecting other groups, such as zinc borohydride or sodium borohydride. Common solvents are compounds of etheric nature, such as tetrahydrofuran and sulfuric ether. The choice of temperature is determined by the activity of the reducing agent, and in most cases it is advisable to carry out the process while cooling with a bath with acetone and dry ice.
    The compounds of general formula 1 exhibit a vasodilating effect and can be used to treat hypertension. In addition, these compounds have anti-ulcer activity.
    Example 1. S-Ji- (Tetrahydropyran-2-yloxymethyl) -2-pyrrolidone.
    In a flask, dried on the flame, under nitrogen atmosphere, load 2.54 g
    (22.1 mmol) 5-p1-hydroxymethylene-2-pyrrolidone and 50 ml of methylene chloride. To this solution, 3.72 g (44.2 mmol) of double-distilled dihydropyran and 0.2 g of p-toluenesulfonic acid were added. The solution is spontaneously heated to room temperature and stirred for 8 hours. After diluting the reaction mixture with 20 MP of ethyl acetate, the solution is extracted twice with 5 ml of saturated sodium bicarbonate solution and once with 10 ml of saturated brine. The organic layer is dried with magnesium sulfate, filtered from the drying agent and the solvent is removed in vacuo, yielding 4.1 g of a yellow oil. This oil is chromatographed on a 50 g column of Merck silica gel. By elution with 1 L of chloroform, insignificant amounts of polar impurities are removed. By zoning with 2% methyl methanol in chloroform and collecting 10 ml of fractions, the product was separated, after removing the solvent in vacuo, 3.95 g of the desired product was obtained as a yellow oil. You5 move 90%.
    Example 2. Synthesis of 1-7- (ethylheptanato) -5- / 5- (tetrahydropyran-2 ylo-xymethyl) -2-pyrrolidone.
    In a flask dried on a flame
    Under nitrogen atmosphere, 0.725 g (18.7 mmol) of 62% sodium hydride dispersion in mineral oil and 10 ml of dry tetrahydrofuran are charged. To this mechanically stirred mixture, 3.74 g (18.7 mmol) of 5-0- (tetrahydropyran-2-yloxymethyl) -2-pyrrolidone are slowly added dropwise into 10 ml of dry tetrahydrofuran, stirred for 30 minutes until completely stopped.
    0 hydrogen evolution.
    Next, 5.34 g (22.5 mmol) of ethyl-7-bromoheptanoate in 15 ml of dry dimethylformamide is added dropwise to this mixture at room temperature, stirred for 5 hours, filtered and then the solvent is removed from the filtrate in vacuo. 100 MP of ethyl acetate are added to the residue and the resulting organic solution is extracted twice with 20 MP each time with water. After drying the organic layer with magnesium sulfate and removing the drying agent from it, the solvent is distilled off from the filtrate under vacuum, a yellow oil is obtained, which is subjected to chromatography on a column filled with 120 g of Merck silica gel in chloroform. Sequential elution with 250 ml of chloroform, 500 ml of 5% ethyl acetate in chloroform, 1 l of 10% ethyl acetate in chloroform and automatic collection of 10 ml fractions carried out the separation and purification of the product. Combine the product fractions and distill off the solvent to obtain 3.9 g of the desired product as a colorless oil, yield: 51%.
    A mixture of 2.98 g (23.5 mmol) of 7-hydroxyheptanitrile, 1.6 (30 mmol) of ammonium chloride, 0.032 g (0.76 mmol) of lithium chloride, 1.91 g (29.3 mmol) of sodium azide and 50 ml of dimethylformamide is held at 1200 ° C under a nitrogen atmosphere with stirring for 18 hours. Then dimethylformamide is distilled off in vacuo, the resulting residue is purified by chromatography or extraction. The 6-OXY-1- (tetrazol-5-nl) -hexane obtained is then treated with phosphorus tribromide; a b-bromo-1- (tetrazol-4-yl) -hexane is obtained, the N-tetragonal opiran-2-yl group is added to according to the method described in example 1.
    PA can be selectively removed using tetra-n-butylammonirfluoride. When applying the acetic acid procedure to 1- (2,2-diethoxy) .til) -5- (tetrahydropyran-2-yloxymethyl) -2-pyrrolidone of example 2, cleavage of the tetrahydropyranyl group is accompanied by acetal cleavage and cyclization. As a result, an equal mixture of the open structure and 4-aza-2-hydroxy-1-oxa-bicyclo-3, 4.0 -nonan-5-one is obtained as a product.
    15
    Example 3. Synthesis of 1- (7-methylheptanate) -5- / -oximethyl-2-pyropolydone.
    79 ml of p-toluenesulfonic acid is added to a solution of 200 ml of methyl alcohol and 3.99 g of tetrahydropyranpyrrolidone and the solution is heated to reflux for 8 hours. After this treatment, the NMR spectrum of the reaction mixture revealed the presence of a small amount of starting ethyl ester. Therefore, the reaction mixture was re-dissolved in 160 ml of methyl alcohol, 0.08 g of p-toluenesulfonic acid was added and the reaction mixture was again heated under reflux for 3 hours. Removal of the solvent in vacuo from the reaction mixture yields a yellow oil, which is dissolved in ethyl acetate, extracted with 10 ml of a 1: 2 mixture of saturated sodium bicarbonate solution and half-saturated Rochelieu saline. The organic phase is dried with magnesium sulfate, filtered, the solvent is evaporated, and the desired product is obtained as a clear yellow oil. Yield 2,528 G | (88%).
    The tetrahydropyran-2-yl group can be removed by hydrolysis in a mixture of 65:35 glacial acetic acid and water for about 18 hours in accordance with the method of example 14.
    In this case, the pyrrolidone ethyl ester group is kept intact.
    The above method of hydrolysis in acetic acid and water can also be used to remove the tetrahydropyranyl protecting group from the other pyrrolidone products of Example 2, which will produce the corresponding 1- (substituted) -5-p-hydroxymethyl-2-pyrrolidones. However, if the tetrazol-5-yl protecting group serves as a tetrahydropyran-2-yl, then it is advisable to use a dimethyl-t-butylsilyl group as a protecting group T. This silyl group This mixture is converted to 1- (substituted) -5- | 1) oxymethyl-2-pyrrolidones in accordance with the following procedure.
    To a solution of 23.04 g (52.0 mmol) of 5-triphenylphosphonyl-pentanoic acid bromide in 46 ml of dry dimethyl sulfoxide was added dropwise 49.3 ml (98.6 mmol) of a binary solution of methyl sulphinylmethyl sodium in dimethyl sulfoxide. To the resulting red solution, 3.27 g (20.8 mmol) -4-aza-2-hydroxy-1-oxa-bicyclo-3, 4.0-nonan-5-one in dry dimethyl sulfoxide (63 ml) After stirring for half an hour, the reaction mass is then poured into 600 ml of ice-cold water and extracted twice with 300 ml portions of ethyl acetate. Ethyl acetate was added to the cold aqueous layer and acidified to pH 3 with 10% hydrochloric acid, after which the aqueous layer was extracted twice with 200 ml of ethyl acetate. The combined organic extracts are washed with water, then brine, and the organic layer is dried with anhydrous sodium sulfate. By concentrating the filtered organic layer, crude 1- (6-carboxyhex-2-eiyl) -5-p-hydroxymethyl-2-pyrrolidone is obtained, which is chromatographed. The acid is then esterified with diazomethane.
    Example 4. Synthesis of 1- (7-methyl heptanato) -5-p-formyl-2-pyrrolidone.
    In a flask dried with a flame, in a nitrogen atmosphere, 0.12286 g (0.5 mmol) of 1 (7-methylheptanato) -5-e-hydroxymethyl-2-pyrrolidone is introduced into 5 ml of dry benzene. 0.1228 g (1.5 mmol) of dimethylaminopropylethylcarbodiimide hydrochloride (DANK) and Of 142 ml (2 mmol) of dimethyl sulfoxide are added to the solution, and 0.108 g (0.55 mgiol) of pyridinium trifluoroacetate are added five minutes later. The reaction mass is stirred at room temperature for 1.75 h in an atmosphere
    nitrogen, after which benzene of Obraec zonus is decanted on the bottom of the flask. The second phase is washed with benzene three times in 5 ml volumes. The benzene solutions are combined and the solvent is removed in vacuo to give 0.152 g of the desired product as a clear yellow oil, which is used immediately without further purification in the subsequent reaction.
    Example 5. Synthesis of 1- (7-methylheptanato) -5-p | - (4-phenylbut-1-ene-3 -onyl) -2-pyrrolidone.
    0.1168 g (2.97 mmol) of a 60% dispersion of sodium hydride in mineral oil and 5 ml of tetrahydrofuran are added to a flame-heated flask under a nitrogen atmosphere, and a solution of 0.7815 g (8.24 mmol) of dimethyl- (3 -phenylpropan-2-onyl) phosphonate in 5 NUi of tetrahydrofuran. After the hydrogen evolution ceases, the mass is a white suspension, which is stirred for 15 minutes. To this suspension, 0.6894 g (2.70 mmol) of 1- (7-methylheptanato) -5-p-formyl-2-pyrrolide in 10 ml of tetrahydrofuran is added over 1 minute. within 5 minutes, the reaction mass is converted to a clear yellow solution, which is stirred for 2 hours, then glacial acetic acid is added to pH 5. The solvent is removed in vacuo and the residue is mixed with 100 ml of ethyl acetate. The organic solution is extracted twice with 10 ml of aqueous saturated sodium bicarbonate solution, three times with 10 ml of water and saturated brine (once with 10 ml). The organic layer is dried with magnesium sulfate, filtered and the solvent is distilled off in vacuo to give 1.141 g of a yellow oil. This the crude product is subjected to chromatography on a column of 35 g of Merck silica gel filled with ethyl acetate. Elution with ethyl acetate and automatic collection of 10 MP fractions allows purification of the product, the product fractions are combined, the solvent is removed in vacuum, 0.614 g of the desired product is obtained as a colorless oil, and the yield is 61% from saturated alcohol.
    Example 6. Synthesis of 1- (7-methylheptanato) -5-p- (3 -oxy-4-phenylbut-yl) -2-pyrrolidone.
    In a flask dried on a flame and equipped with a magnetic stirrer in an atmosphere of nitrogen, 0.5784 g (1.56 mmol) of 1- (7-methylheptanato) -j-jj - (4-phenylbut-1-en-3 It) -2-pyrrolidone in 20 ml of dry tetrahydrofuran. The clear, colorless solution is cooled to -780 ° C, and 1.56 ml (1.56 mmol) of triethyllithiorohydride are added dropwise to it through a syringe over 15 minutes. After 1 h, thin layer liquid chromatography showed the absence of starting enone. The reaction is stopped by adding glacial acetic acid to pH 5 and then the solvent is distilled off in vacuo. The residue was dissolved in 50 ml of ethyl acetate and this organic solution was then extracted with half-saturated aqueous solution of sodium bicarbonate (ml), water (4 ml) and saturated brine (1 x 10 ml). The organic layer is dried
    magnesium sulfate, filtered, and the solvent was distilled off in vacuo to obtain 700 mg of a crude product. The product is chromatographed on a column of 9 g of silica gel in ethyl acetate. Elution with ethyl acetate and automatic collection of 5 ml fractions separated the product from impurities. The product fractions are combined, the solvent is removed in vacuo,
    0.298 g of the expected product is obtained.
    0 in the form of a colorless oil. Yield 51%.
    Example 7. Synthesis of 1- (6 -carboxyhexyl) -5-p- (3 -oxy-4-phenyl-but-1-yl) -2-pyrrolidone.
    To a solution of 69 mg (0.185 mmol)
    5 1 (7-methylheptanato) -5-p- (3-hydroxy-4-phenylbut-1-yeni) -2-pyrrolidone in 3 ml of methyl alcohol was added 0.185 ml (0.185 ml-eq.) Of a one-normal solution of sodium hydroxide.
    Q The solution is heated under reflux for 8 hours and then neutralized to pH 4 by the addition of glacial acetic acid. The solvent is removed in vacuo and the oily residue is dissolved in 15 ml of ethyl acetate. The organic solution is extracted with water (2 ml each time) and saturated brine (2 ml once), dried over magnesium sulfate and filtered. The solvent is removed in vacuo to give the desired.
    0 product in the form of a yellow oil. The output of 59.4 mg (89%).
    Example 8. Synthesis of 1- (7-methylheptanato) -5- / 3- (4-phenoxybut-1. En-3 -onyl) -2-pyrrolidone.
    5 In a flask dried on a flame, under nitrogen atmosphere, 22 mg (0.55 mmol) of sodium hydride dispersion in mineral oil and 5 ml of tetrahydrofuran are loaded, a solution is added
    Q 0.1549 g (0.6 mmol) of dimethyl- (3-phenoxypropan-2-onyl) -phosphonate in 5 ml of tetrahydrofuran. After the evolution of hydrogen ceases, a clear, pale yellow solution is obtained, which is stirred for 15 minutes. To this solution, 0.1277 g (0.5 mmol) of 1- (7-methylheptanato) -5- | L-formyl-2-pyrrolidone in 5 ml of tetrahydrofuran is added over one minute. The resulting solution is stirred for the next two hours. The reaction is stopped by adding glacial acetic acid to pH 5. The solvent is distilled off in vacuo, and the residue is dissolved in 50 ml of ethyl acetate. The organic solution is extracted with a saturated aqueous solution of sodium bicarbonate (twice 5 ml), water (twice 5 ml) and saturated brine (once, 5 ml). The organic layer was dried with magnesium sulfate, filtered, and the solvent was removed in vacuo to give 0.231 g of a yellow oil. This crude product is chromatographed on a column with 25 g of Merck silica gel filled with cyclohexane. The product was purified by elution with 50% chloroform in cyclohexane and automatically collecting 10 ml fractions, the product fractions were combined, the solvent was distilled off in vacuo, to give 53.6 mg of the desired product. Yield 28%.
    Example 9. Synthesis of 1- (7-me. Ethylheptanato) -5 - (- (3 -oxy-4-phenoxybut-1-enyl) -2-pyrrolidone.
    In a flask dried on a flame and equipped with a magnetic stirrer and a thermometer, under nitrogen atmosphere is charged 0.1046 g (0.27 mmol) of 1- (7-methylheptanato) -5- (4-phenoxybut-1-en-3 -onyl ) -2-pyrrolidone in 5 ml of dry tetrahydrofuran .. The clear, colorless solution is cooled before and for 15 minutes, triethyllithium hydride is added dropwise via a syringe. After 1 h, the reaction was stopped by adding glacial acetic acid to pH 5, and then the solvent was distilled off in vacuo. The residue is dissolved in 25 ml of ethyl acetate and this organic solution is then extracted with a half-saturated aqueous solution of sodium bicarbonate (5 ml once), water (once 10 mp) and saturated brine (once 10 mp). The organic layer was dried with magnesium sulfate, filtered, and the solvent was distilled off in vacuo to give 101 mg of a crude product. This product is chromatographed on a column with 25 g of silica gel in benzene. Purification of the product from impurities was carried out by elution with ethyl acetate and automatic collection of 5 ml fractions, but this did not achieve separation into two epimers. The fractions were combined, the solvent was removed in vacuo to give 85.6 mg of the desired product. Yield 82%
    Example 10. Synthesis of 1- (6 -carboxyhexyl) -5-0- (3-hydroxy-4 -phenoxy-but-l-yl) -2-.pyrrolidone.
    To a solution of 50 mg (0.128 mmol) of 1- (7-methylheptanato) (3 -oxy-4-phenoxy-but-l-yl) -2-pyrrolidone in 8 ml of methyl alcohol was added "t 0.128 ml (0.128 mmol-) of one-boron oxide hydrate on three . The solution was heated under reflux for 8 hours, then neutralized to pH 4 by the addition of glacial acetic acid. The solvent was distilled off in vacuo, and the oily residue was dissolved in 15 ml of ethyl acetate. The organic solution is extracted with water (2 ml each time) and saturated brine (once, 2 ml), dried over magnesium sulfate and filtered. The solvent is evaporated in vacuo to give the desired product as a yellow oil. Yield 48 mg (99%).
    Example 11. 128 mg (0.612 mmol) of 1- (7-methylheptanato) (4-hydroxy-4-phenylbut-1-anyl) -2-pyrrolidone and 5 ml of methylene chloride are introduced into a flame-dried flask under a nitrogen atmosphere. 0.062 ml (0.684 mmol) of double-distilled dihydropyran and 3 mg of p-toluenesulfonic acid are added to this solution. The solution is then allowed to spontaneously take room temperature and stirred for 8 hours. The reaction mass is diluted with 10 ml of ethyl acetate, extracted with saturated sodium bicarbonate solution (twice 2 ml) and saturated brine (once, 5 ml). The organic layer was dried with magnesium sulfate, filtered, and the solvent was evaporated in vacuo to give 0.135 g of a yellow oil. The last chromatographic on a column of 15 g of silica gel in chloroform. Minor polar impurities are removed by elution with 1 L chloroform; The separation and purification of the product is carried out by elution with 2% methyl alcohol in chloroform and automatic collection of 10 m fractions. the product fractions were combined and the solvent was removed in vacuo, to give 0.1756 g of the desired product as a yellow oil.
    Example 12, Synthesis of 1- (7-methylheptanato) -5-p- (3-tetrahydropyra-2 -yloxy-4-phenylbutyl) -2-pyrrolidone.
    To a solution of 156.5 mg (0.342 mmol) of 1- (7-methylheptanato) (3-tetrahydropyran-2 -yloxy-4-phenylbut-1-enyl) -2-pyrrolidone in 10 ml of ethyl acetate is added 31 mg of 10% palladium on the charcoal and the whole mixture is placed in a Parr type hydrogenation apparatus and shaken at a pressure of 51 pounds per KBi. The mixture is then filtered through Celite to remove the catalyst and the solvent is distilled off from the filtrate. 158.2 mg of the expected product are obtained.
    Example 13. Synthesis of 1- (6 carboxyhexyl) -5- | 3- (3-tetrahydropyran-2 -yloxy-phenylbutyl) -2-pyrrolidone.
    To a solution of 1,582 mg (0.342 mmol) of 1- (7-methylheptanato) -5- / 5- (3-tetrahydropyran-2-yloxy-4-phenylbutyl) -2-pyrrolidone in 5 ml of methyl alcohol is added 0.342 ml (0.342 mmol) mononormal sodium hydroxide The reaction mass is boiled for 8 hours under reflux and then neutralized to pH 4 by the addition of glacial acetic acid.
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of obtaining derivatives of feast; lidine of the general formula 1 wherein R- is phenyl or phenoxy;
    R f is hydrogen, methyl or ethyl, is a single or cis double bond, is a single or trans double bond, is a group 'OH or Η (/ <' H, resulting in that
    Mutil the compound of general formula II , from where T is tetrahydropyranyl or dimethyl-tert-butylsilyl group, the compounds have chlorine, are reacted ! by the general formula III
    With O 0R.], Where W and the above values, and bromine or iodine, remove the protective group T, oxidize the resulting alcohol to an aldehyde, which is treated with phosphonate of the general formula IV (R x 0) 2 P (= 0) CH 2 COCH 2 R where R has the above meanings, is alkyl with 1-3 carbon atoms, followed by reduction of compounds of the general formula 1, where M is oxygen, and, if necessary, hydrogenation to obtain compounds of the general formula 1, where W is a single bond, followed by isolation target product.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1031407A3|1983-07-23|Process for preparing derivatives of |-16-phenoxy-9-ketoprostatrienic acid or their acid addition salts
    US4177346A|1979-12-04|1,5-Disubstituted-2-pyrrolidones
    SU850000A3|1981-07-23|Method of preparing pyrrolidine derivatives
    US4161597A|1979-07-17|N-alkyl-14-hydroxymorphinans and derivatives
    BG97471A|1994-03-24|Process for the preparation of 13,14-dihydro-15|-17-phenyl-18,19,20-trinor-pgf2ó esters
    US4415736A|1983-11-15|Certain tetrahydropyridine intermediates
    RO112031B1|1997-04-30|Benzopyrane derivates and ltb4 antagonists, procedures for their preparation, pharmaceutical composition and method for inhibition of binding the receiver with ltb4
    US4271314A|1981-06-02|4,5-Unsaturated prostanoic acid derivatives
    SU900806A3|1982-01-23|Process for producing prostaglandin derivatives
    US4021452A|1977-05-03|2,5-Dihydro-2,5-dialkoxyfuran derivatives
    US3624144A|1971-11-30|Zearalenone intermediates and their preparation
    US4120873A|1978-10-17|9-Hydroxy-7,8,9,10-tetrahydro-6H-dibenzo[b][d]pyranones
    DK147070B|1984-04-02|ANALOGY PROCEDURE FOR THE PREPARATION OF 13,14-DEHYDRO-11-DEOXY PROSTAGLANDINES
    JPH0747591B2|1995-05-24|Intermediates of trans-4-substituted-S-prolines
    EP0050849B1|1984-01-11|4,5-unsaturated prostanoic acid derivatives
    US3932467A|1976-01-13|Process for the production of 2β-formyl 3α-protected hydroxy-5-oxocyclopentane-1α-heptanoic acids and esters corresponding
    EP0006355A1|1980-01-09|Mixed anhydride steroid intermediate and process for preparing steroid intermediates
    US3952033A|1976-04-20|Furan intermediates and process for synthesis of 4-hydroxycyclopetenones, prostaglandin synthesis intermediates
    CA1173051A|1984-08-21|Total synthesis of 1rs,4r,5rs-4-|-4-methyl-3,8-dioxabicyclo¬3.2.1| octane-1-acetic acid
    US4212828A|1980-07-15|Novel process for asymmetric synthesis of optically active 2-alkanoyl-1,2,3,4-tetrahydro-2-naphthol compounds
    SU845774A3|1981-07-07|Method of preparing 13,14-dehydro-11-desoxyprostaglandins
    CA1095077A|1981-02-03|Process for the production of a derivative of phenylacetic acid
    KAWASHIMA et al.1990|Synthesis and platelet aggregation-inhibitory activities of novel 3-| azetidin-2-one derivatives. I
    KR810000657B1|1981-06-16|Process for preparing pyrrolidone compound
    US4213907A|1980-07-22|Prostaglandin intermediates
    同族专利:
    公开号 | 公开日
    CH624934A5|1981-08-31|
    FR2369260B1|1982-02-12|
    SE7708642L|1978-02-07|
    PT66891B|1979-01-26|
    JPS5531147B2|1980-08-15|
    BE857506A|1978-02-06|
    JPS585196B2|1983-01-29|
    NZ184806A|1980-04-28|
    DE2735904A1|1978-02-09|
    AU2751577A|1979-02-08|
    HU180273B|1983-02-28|
    NO772752L|1978-02-07|
    PH17398A|1984-08-08|
    JPS5321159A|1978-02-27|
    PL112931B1|1980-11-29|
    CS221269B2|1983-04-29|
    FI70009B|1986-01-31|
    IE45505L|1978-02-06|
    SU703016A3|1979-12-05|
    IL52615A|1981-09-13|
    SU818480A3|1981-03-30|
    FR2369260A1|1978-05-26|
    IE45505B1|1982-09-08|
    PT66891A|1977-09-01|
    JPS5555161A|1980-04-22|
    AU508007B2|1980-03-06|
    LU77936A1|1978-04-27|
    GR68688B|1982-02-01|
    GB1556569A|1979-11-28|
    FI772376A|1978-02-07|
    NL7708637A|1978-02-08|
    DK352077A|1978-02-07|
    SE423813B|1982-06-07|
    CA1077948A|1980-05-20|
    YU192577A|1983-04-30|
    AT362887B|1981-06-25|
    ZA774704B|1978-06-28|
    ES461388A1|1978-12-01|
    AR217080A1|1980-02-29|
    GB1556570A|1979-11-28|
    ATA579477A|1980-11-15|
    IL52615D0|1977-10-31|
    DD143768A5|1980-09-10|
    DD136135A5|1979-06-20|
    BG31073A3|1981-10-15|
    ES471349A1|1979-09-16|
    PL200124A1|1978-05-22|
    FI70009C|1986-09-12|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1386146A|1972-05-03|1975-03-05|Ici Ltd|Cyclopentane derivatives|
    JPS5751385B2|1974-06-24|1982-11-01|
    JPS5751387B2|1974-06-28|1982-11-01|
    US3975399A|1974-08-06|1976-08-17|E. I. Du Pont De Nemours And Company|1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones|
    DE2528664A1|1975-06-27|1977-01-13|Hoechst Ag|PYRROLIDONE AND THE METHOD FOR MANUFACTURING THEIR|JPS635217B2|1979-12-27|1988-02-02|Canon Kk|
    US4321201A|1980-09-22|1982-03-23|E. I. Du Pont De Nemours And Company|Optically active tert-alkyl 7- heptanoates|
    JPH0579533B2|1983-01-25|1993-11-02|Mitsubishi Electric Corp|
    IL141120D0|2000-01-31|2002-02-10|Pfizer Prod Inc|Use of prostaglandinreceptor 4selective agonists for the treatment of acute and chronic renal failure|
    PL362030A1|2000-11-27|2004-10-18|Pfizer Products Inc.|Ep4 receptor selective agonists in the treatment of osteoporosis|
    DE60239343D1|2001-07-23|2011-04-14|Ono Pharmaceutical Co|MEDICINE FOR THE TREATMENT OF DISEASES COMING WITH BONE SCUM, WITH EP4 AGONIST AS AN ACTIVE AGENT|
    EP1487437B1|2002-03-18|2006-08-16|Pfizer Products Inc.|Use of selective ep4 receptor agonists for the treatment of diseases|
    US6573294B1|2002-05-14|2003-06-03|Allergan, Inc.|8-azaprostaglandin analogs as agents for lowering intraocular pressure|
    JP4582456B2|2003-01-21|2010-11-17|小野薬品工業株式会社|8-Azaprostaglandin derivatives and pharmaceutical use thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US71236276A| true| 1976-08-06|1976-08-06|
    [返回顶部]